7 Cheapest GLP-1 Providers (2026)

Two different products: what you need to understand first

'GLP-1' covers a class of medications, not a single drug. The two most relevant in 2026 are semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro). Tirzepatide is a dual GIP/GLP-1 agonist — it works on two receptor types instead of one — and has shown greater average weight loss in head-to-head trials. Both are available as brand-name FDA-approved products and as compounded versions.

Compounded versions are made by 503A compounding pharmacies under individual-patient prescriptions. They are significantly cheaper than brand-name but are not FDA-approved as finished products. Both semaglutide and tirzepatide can be compounded legally under current rules, but the regulatory picture is actively evolving. This is the most important caveat in any GLP-1 price comparison right now.

Henry Meds — cheapest bundled compounded semaglutide

Henry Meds charges a single monthly price that includes everything: the compounded semaglutide (oral or injectable), clinician visits, lab review, and shipping. The oral version at $249/mo is currently the most affordable all-in compounded semaglutide we can verify. Unlike some competitors, the price does not change as the dose escalates.

• Pros: clear all-in pricing; no membership fee stacked on top; no dose-escalation price hikes
• Cons: compounded product, not FDA-approved as a finished drug
• Best for: women who want the lowest consistent monthly cost for compounded semaglutide

Fridays — cheapest on an annual commitment

Fridays' annual plan brings compounded semaglutide to ~$150/mo — among the lowest prices available anywhere for a full-service program. The catch is commitment: month-to-month runs $249/mo, and the discount only applies if you pay for 12 months at once. The program includes dietitian access, lifestyle coaching, and app support bundled in.

• Pros: cheapest annual rate; dietitian and coaching included; no separate membership
• Cons: annual commitment required for best price; BBB complaints about refund processes
• Best for: women committed to a year-long GLP-1 program who want the lowest possible annual cost

Curex — cheapest for compounded tirzepatide

Curex offers compounded tirzepatide at roughly $199/mo all-in — the lowest all-in tirzepatide price we can verify from a service that includes the consult and shipping in that figure. The price holds at the starter dose and should be confirmed before assuming it applies at higher titration levels.

Mochi Health — flat-price compounded tirzepatide across all doses

Mochi Health splits its cost into medication plus membership: $199 for the compounded 503A tirzepatide and roughly $79/mo for the membership, landing at about $278/mo all-in. The flat price holds across every dose, so titrating up never raises the bill — useful if you expect to reach higher maintenance levels.

• Pros: flat price across all doses; no dose-escalation hikes
• Cons: membership billed on top of the medication; compounded product, not FDA-approved as a finished drug
• Best for: women on compounded tirzepatide who want a single predictable price from starter to maintenance dose

NovoCare — cheapest brand-name entry point (Wegovy)

NovoCare's intro pricing is the most affordable way into brand-name Wegovy: $199/mo for the first two fills at starter doses (0.25mg–0.5mg). It rises to $349/mo at 0.5–1mg and $499/mo at 2mg, so the low rate only covers the first stretch of titration. It is the only FDA-approved semaglutide option in this comparison at an entry price this low.

• Pros: brand-name FDA-approved Wegovy; lowest intro price for brand-name semaglutide
• Cons: price rises significantly after the first two fills; not bundled with visits or coaching
• Best for: women who want brand-name Wegovy and are starting at a low, new-to-program dose

LillyDirect — the only FDA-approved tirzepatide at this price tier

LillyDirect's self-pay Zepbound vials start at $299/mo for the 2.5mg dose, rising to $399/mo at 5mg and $449/mo at 7.5–15mg. It is more expensive than compounded tirzepatide, but the only FDA-approved option at this price range. Refills need to land within a 45-day window; miss it and prices jump to $499–$699.

• Pros: FDA-approved tirzepatide; no membership fee stacked on top
• Cons: pricier than compounded tirzepatide; refill window is tight
• Best for: women who want FDA-approved tirzepatide and don't need the lowest possible price

Hims & Hers — brand-name Wegovy with a separate membership

Hims & Hers offers brand-name Wegovy starting around $249/mo for the oral form or $299/mo for the injectable, with a $149/mo membership billed separately on top. As of March 2026 it no longer offers compounded semaglutide to new patients, so the brand-name route is the only option here — which makes the stacked membership a meaningful part of the real cost.

• Pros: brand-name FDA-approved Wegovy; oral and injectable both available
• Cons: $149/mo membership stacked on top; no compounded semaglutide for new patients as of March 2026
• Best for: women who specifically want brand-name Wegovy and value the Hims & Hers platform

Annual cost comparison

At ongoing maintenance doses (after the intro period), the annual cost range looks like this: Henry Meds compounded semaglutide injection = ~$3,564/yr. Fridays compounded semaglutide (annual plan) = ~$1,800/yr. LillyDirect Zepbound 5mg = ~$4,788/yr. NovoCare ongoing (Wegovy, post-intro) = ~$4,188/yr. Henry Meds oral semaglutide = ~$2,988/yr. Brand-name at retail list (no savings program) = $16,000–$19,000+/yr.

Compounding legal status: what to know in 2026

FDA has been tightening enforcement around compounded GLP-1 medications since 2025. Semaglutide is no longer on the official drug shortage list, but 503A pharmacies can still legally compound it for individual patients under a prescriber's order. Tirzepatide similarly: broad 503B outsourcing facility compounding has faced restriction, but individual-patient 503A compounding continues.

This means your compounded GLP-1 prescription can still be filled legally, but the pathway is narrower than it was in 2023–2024 when shortage-based compounding was more broadly permitted. Ask your provider specifically which pharmacy model they use and whether they have contingency plans if regulatory conditions shift.